Mylan and Revance Therapeutics agreed to work together to develop a biosimilar of Allergan's Botox, which is indicated for the treatment of wrinkles. Under the deal, Revance will receive an upfront payment of $25 million.
Mylan, Revance enter licensing deal on Botox biosimilar
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.